Novo Nordisk’s Ozempic may reduce risk of Alzheimer’s disease: study
Steve Christo - Corbis | Corbis News | Getty ImagesNovo Nordisk's blockbuster diabetes drug Ozempic may reduce the risk of developing Alzheimer's disease, suggesting its potential to delay or prevent the memory-robbing condition, according to a study released Thursday. Semaglutide, the active ingredient in Ozempic, was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in patients with Type 2 diabetes compared with seven other diabetes medications. That includes insulin and older so-called GLP-1 drugs similar to Ozempic, the research said. Alzheimer's disease is often diagnosed in the mild dementia stage, when a person has significant trouble with memory and thinking. Almost 7 million Americans have the condition, the fifth-leading cause of death for adults over ...










